Creative Planning reduced its stake in TriMas Co. (NASDAQ:TRS – Free Report) by 8.7% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 24,700 shares of the industrial products company’s stock after selling 2,356 shares during the quarter. Creative Planning owned about 0.06% of TriMas worth $631,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. raised its stake in shares of TriMas by 2.3% during the 1st quarter. Vanguard Group Inc. now owns 4,358,524 shares of the industrial products company’s stock worth $116,503,000 after buying an additional 100,068 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of TriMas by 0.8% in the second quarter. Dimensional Fund Advisors LP now owns 2,530,874 shares of the industrial products company’s stock valued at $64,689,000 after purchasing an additional 19,436 shares during the period. Kennedy Capital Management LLC raised its position in shares of TriMas by 197.8% during the 1st quarter. Kennedy Capital Management LLC now owns 273,200 shares of the industrial products company’s stock valued at $7,303,000 after buying an additional 181,447 shares during the period. Bank of New York Mellon Corp grew its holdings in shares of TriMas by 8.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 262,294 shares of the industrial products company’s stock worth $6,704,000 after purchasing an additional 19,849 shares during the period. Finally, First Eagle Investment Management LLC raised its stake in shares of TriMas by 26.2% in the 2nd quarter. First Eagle Investment Management LLC now owns 240,006 shares of the industrial products company’s stock valued at $6,135,000 after acquiring an additional 49,800 shares during the period. 99.42% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Separately, BWS Financial reaffirmed a “buy” rating and set a $40.00 price objective on shares of TriMas in a research report on Wednesday, October 9th.
TriMas Trading Down 8.1 %
Shares of TRS opened at $24.87 on Tuesday. TriMas Co. has a 1-year low of $22.45 and a 1-year high of $28.51. The stock has a market cap of $1.01 billion, a price-to-earnings ratio of 25.38 and a beta of 0.66. The firm has a 50 day simple moving average of $25.83 and a 200-day simple moving average of $25.82. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.82 and a quick ratio of 1.48.
TriMas Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, November 12th. Investors of record on Tuesday, November 5th will be paid a dividend of $0.04 per share. This represents a $0.16 dividend on an annualized basis and a dividend yield of 0.64%. The ex-dividend date of this dividend is Tuesday, November 5th. TriMas’s dividend payout ratio is currently 16.33%.
About TriMas
TriMas Corporation engages in the design, development, manufacture, and sale of products for consumer products, aerospace, and industrial markets worldwide. The company operates through Packaging, Aerospace, and Specialty Products segments. The Packaging segment offers dispensing products, such as foaming and sanitizer pumps, lotion and hand soap pumps, beverage dispensers, perfume sprayers, and nasal and trigger sprayers; polymeric and steel caps and closures comprising food lids, flip-top and beverage closures, child resistance caps, drum and pail closures, and flexible spouts; polymeric jar products; integrated dispensers; bag-in-box products; and consumable vascular delivery and diagnostic test components under the Rieke, Taplast, Affaba & Ferrari, Intertech, Omega, and Rapak brands.
Featured Stories
- Five stocks we like better than TriMas
- How to Start Investing in Real Estate
- Intel: Is Now the Time to Be Brave?
- Top Stocks Investing in 5G Technology
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- How to Evaluate a Stock Before Buying
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for TriMas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriMas and related companies with MarketBeat.com's FREE daily email newsletter.